DEXAMETHASONE- dexamethasone injection, solution MWI (Vet One)

DEXAMETHASONE INJECTION 2 mg/mL Dexamethasone Sterile Injection

Solution for intravenous or intramuscular injection

Veterinary

CAUTIONFederal Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

DEXAMETHASONE INJECTION 2 mg/mL is a synthetic analogue of prednisolone, having similar but more potent anti-inflammatory therapeutic action and diversified hormonal and metabolic effects. Modification of the basic corticoid structure as achieved in DEXAMETHASONE INJECTION 2 mg/mL offers enhanced anti-inflammatory effect compared to older corticosteroids. The dosage of DEXAMETHASONE INJECTION 2 mg/mL required is markedly lower than that of prednisone and prednisolone.

DEXAMETHASONE INJECTION 2 mg/mL is not species-specific; however, the veterinarian should read the sections on **INDICATIONS**, **DOSAGE**, **SIDE EFFECTS**, **CONTRAINDICATIONS**, **PRECAUTIONS**, and **WARNINGS** before this drug is used.

DEXAMETHASONE INJECTION 2 mg/mL is intended for *intravenous or intramuscular* administration. Each mL contains 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives, 4.75% alcohol, HCl to adjust pH to approximately 4.9, water for injection q.s.

EXPERIMENTAL STUDIES

Experimental animal studies on dexamethasone have revealed it possesses greater anti-inflammatory activity than many steroids. Veterinary clinical evidence indicates dexamethasone has approximately twenty times the anti-inflammatory activity of prednisolone and seventy to eighty times that of hydrocortisone. Thymus involution studies show dexamethasone possesses twenty-five times the activity of prednisolone. In reference to mineralocorticoid activity, dexamethasone does not cause significant sodium or water retention. Metabolic balance studies show that animals on controlled and limited protein intake will exhibit nitrogen losses on exceedingly high dosages.

INDICATIONS

DEXAMETHASONE INJECTION 2 mg/mL is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine.

As supportive therapy, DEXAMETHASONE INJECTION 2 mg/mL may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. DEXAMETHASONE INJECTION 2 mg/mL may be used intravenously as supportive therapy when an immediate hormonal response is required.

Bovine KetosisDEXAMETHASONE INJECTION 2 mg/mL is offered for the treatment of primary ketosis. The gluconeogenic effects of DEXAMETHASONE INJECTION 2 mg/mL, when administered intramuscularly, are generally noted within the first 6 to 12 hours. When DEXAMETHASONE INJECTION 2 mg/mL is used intravenously, the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. Acetone bodies are reduced to normal concentrations usually within 24 hours. The physical attitude of animals treated with DEXAMETHASONE INJECTION 2 mg/mL brightens and appetite improves, usually within 12 hours. Milk production, which is suppressed as a compensatory reaction in this condition,

begins to increase. In some instances, it may even surpass previous peaks. The recovery process usually takes from 3 to 7 days.

Supportive TherapyDEXAMETHASONE INJECTION 2 mg/mL may be used as supportive therapy in mastits, metritis, traumatic gastritis, and pyelonephritis, while appropriate primary therapy is administered. In these cases, the corticosteroid combats accompanying stress and enhances the feeling of general well-being. DEXAMETHASONE INJECTION 2 mg/mL may also be used as supportive therapy in inflammatory conditions, such as arthritic conditions, snake bite, acute mastitis, shipping fever, pneumonia, laminitis, and retained placenta.

EquineDEXAMETHASONE INJECTION 2 mg/mL is indicated for the treatment of acute musculoskeletal inflammations, such as bursitis, carpitis, osselets, tendonitis, myositis, and sprains. If boney changes exist in any of the conditions, joints, or accessory structures, responses to DEXAMETHASONE INJECTION 2 mg/mL cannot be expected. In addition, DEXAMETHASONE INJECTION 2 mg/mL may be used as supportive therapy in fatigue, heat exhaustion, influenza, laminitis, and retained placenta provided that the primary cause is determined and corrected.

ADMINISTRATION AND DOSAGE

Therapy with DEXAMETHASONE INJECTION 2 mg/mL, as with any other potent corticosteroid, should be individualized according to the severity of the condition being treated, anticipated duration of steroid therapy, and teh animal's threshold or tolerance for steroid excess.

Treatment may be changed over to DEXAMETHASONE INJECTION2 mg/mL from any other glucocorticoid with proper reduction or adjustment of dosage.

Bovine - DEXAMETHASONE INJECTION 2 mg/mL - 5 to 20 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

Equine - DEXAMETHASONE INJECTION 2 mg/mL - 2.5 to 5 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

CONTRAINDICATIONS

Except for emergency therapy, do not use in animals with chronic nephritis and hypercorticalism (Cushing's syndrome). Existence of congestive heart failure, diabetes, and osteoporosis are relative contraindications. Do not use in viral infections during the viremic stage.

PRECAUTIONS

Animals receiving DEXAMETHASONE INJECTION 2 mg/mL should be under close observation. Because of the anti-inflammatory action of corticosteroids, signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucocorticoids may result in sodium retention, fluid retention, potassium loss, and weight gain.

DEXAMETHASONE INJECTION 2 mg/mL may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.

Doses greater than those recommended in horses may produce a transient drowsiness or lethargy in some horses. The lethargy usually abates in 24 hours.

Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapid acting corticosteroid should be considered in unusually stressful situations.

WARNINGS

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

SIDE EFFECTS

Side effects, such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria have occurred following the use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs and cats.

Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Corticosteroids reportedly cause laminitis in horses.

HOW SUPPLIED

DEXAMETHASONE INJECTION 2 mg/mL, 100 mL multiple dose vial.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F).

Protect from freezing

ANADA#: 200-324, Approved by FDA

WARNING

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Usual Dose

Bovine-5 to 20 mg Equine-2.5 to 5 mg

EACH mL CONTAINS: 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 methylparaben and 0.2 mg propylparaben as preservatives, 4.75% alcohol, HCl to adjust pH to approximately 4.9, water for injection q.s.

EACH mL CONTAINS: 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives, 4.75% alcohol, HCI to adjust pH to approximately 4.9, water for

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).

Protect from freezing

READ ACCOMPANYING DIRECTIONS CAREFULLY.

Lot No.

Exp. Date

NDC 13985-533-03



Dexamethasone

Injection 2 mg/mL

Dexamethasone Sterile Injection

Veterinary

FOR ANIMAL USE ONLY

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ANADA# 200-324, Approved by FDA

V1 501012

MULTIPLE DOSE VIAL Net Contents: 100 mL

100 mL

Warning: A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for yeal.

Usual Dose:

Bovine - 5 to 20 mg Equine - 2.5 to 5 mg

For intravenous or intramuscular injection.

Manufactured by: Sparhawk Laboratories Lenexa, KS 66215 Distributed by: MWI Boise, ID 83705

www.VetOne.net

(D)

D-2953-04 Rev. 10/17

OPEN HERE



pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and mentils.

osair, realized policinal, and mention.

Additionally, conflootenistic administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congenital anomalies including determed forelegs phocomelia, and ansasrca have been reported in offspring of dogs which received conflootenistic during pregnancy.

SIDE EFFECTS
Side effects, such as SAP and SGPT enzyme elevations, weight loss, anoroxia, polydipsia, and polyuria have occurred following the use of synthetic confootracies in days, fronting and diarrhera (occasionally bloody) have been observed in dogs and cats.

Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

HOW SUPPLIED

DEXAMETH/SOME INJECTION 2 mg/mL, 100 mL multiple dose vial.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and permitted 86°F). Protect from freezing

ANADA#: 200-324, Approved by FDA



Manufactured by: Sparhawk Laborat Lenexa, KS 66215

V1 501012

Warning: A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for yeal.

Usual Dose: Bovine - 5 to 20 mg Equine - 2.5 to 5 mg

For intravenous or intramuscular injection.





DEXAMETHASONE INJECTION 2 mg/mL Solution for intravenous or intramuscular injection Veterinary

eral law restricts this drug to use by or on the order of a licensed

DESCRIPTIONS PLECTION 2 mg/ml, is a synthetic analogue of DEDAMPHISSONE NUECTION 2 mg/ml, is a synthetic analogue of DEDAMPHISSONE NUECTION 2 mg/ml, and restable of the production, the sing similar but more potent and restables effects. Modication of the basic controlled synthesis as achieved in DEDAMPHISSONE RECTION 2 mg/ml, offers enhanced and-enhanced synthesis companed to deer confusionistics. The disage of DEDAMPHISSONE MEETING 2 mg/ml, regulated is manifestly lower than that of productions and productions.

DEXAMETHASONE INJECTION 2 mg/ml, is not species-specific; however, the veterinarian should read the sections on INDICATIONS, DOGAGE, SIDE EFFECTS, CONTRANDICATIONS, PRECAUTIONS, and WARNINGS before this drug is used.

DEXAMETH/SSNE NUECTION 2 majors. is intended for intoverous or intransecular administration. Each ml. contains 2 mg dexamethosone, 500 mg polyethylene glycol 400,9 mg dexamethosone, 500 mg polyethylene glycol 400,9 mg dexply alcohol, 1,5 mg methylorasche and 0.2 mg propyloraschen as preservatives, 4,75% alcohol, HO10 adjust pH to approximately 4.9, water for injection q.s.

alcoid, RIO to adjust pit ha approximately 4.9, whele for injection as. DPFRIMENTAL SUDIES

Experimental animal studies on documentamone have revealed it properties. The province of the processes greater and-finalmentary suchly than many sterricks, letherway clinical evidence indicates documentamone has approximately benefit pills that the artificiant processes programments processes produced by these the artificiant processes and processes that the processes that

cover and equine.

As supportive therapy, DEXAMETHASINE NJECTION 2 mg/ml, may be used in the management of various rheumatic, allergic, dermatilogic, and other diseases known to be responsed of emitted that the state of the st

immediath normout response is required.

Bother Robosi
DENMETHSON N.ECTON 2 regims, is offered for the treatment of primary lectors. The disconsoperic effects of DENMETHSON N.ECTON 2 regims, when administered inframracularly, are generally reduct within the first to 12 to 2 to 10.00.

N.ECTON 2 regims, is used intranscensely, the effects may be roded source. Book signate when the to harmst level step of any offered rote to income level to the control level of the control of the con

Supportive Thirapy
DEVAMETH/SONE NULECTION 2 mg/ml, may be used as supportive
therapy in mastifs, netrilis, itsuradic gastrilis, and pyelonephrilis,
white appropriate primary therapy is administered. In these cases, the
conficientiand contains accompanying stress and enhances the feeling

of general well-being.

DEVAMETHASONE NUECTION 2 mg/ml, may also be used as supportive threatly in inflammatory conditions, such as arthrific conditions, snake bite, acute mastifis, shipping fever, pneumonia, laminitis, and retained placenta.

Equine
DEWIETHORNE RICCTON 2 mg/ml, is indicated for the brushment
of acute musclosideated inflammators, such as brailin, carpidi,
consider, bendoin, a region, and option; in thosy offence occurred,
the condition, pions, or accessory structures, responses to
DEWIETHORNE RECETION 2 mg/ml; carpid to addition, DEWIETHORNE RECETION 2 mg/ml; may be used as
supportive through indust heat of hardsens finished acute of
retained placeral provision fails to the primary cause is determined and
constitute.

Treatment may be changed over to DEXAMETHASONE INJECTION 2 mg/ml. from any other glucocorticoid with proper reduction or adjustment of dosage.

5

rine - DEXAMETHASONE INJECTION 2 mg/mL - 5 to 20 mg Desamethasone Powder may be administered or the parenteral dose repeated as needed.

Equine - DEVAMETHASONE INJECTION 2 mg/mL - 2.5 to 5 mg

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

Implication as involved.

CONTRAINDICATIONS

Except for emergency therapy, do not use in animals with chronic nephritis and hyperconficialism (Quahing's syndrome). Existence of congestive heart failure, diabetes, and obseptovosis are relative contraindications. Do not use in viral infections during the viremic

PRECAUTIONS
Animals receiving DEVANETH/SONE INJECTION 2 mg/mL should be under close observation. Because of the arti-inflammatory action of confoosteracids, signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucoconfoolids may

result in sodium retention, fluid retention, potassium loss, and weight

DECAMETHASONE INJECTION 2 mg/mL may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.

Doses greater than those recommended in horses may produce a transient drawsiness or lethargy in some horses. The lethargy usually abates in 24 hours.

Use of confooterwisk, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdraws, it, patients prescript receiving or receiving or receiving or receiving or receiving or receiving or receiving with a rapid admig confootseroid should be considered in unusually stressful situations.

DEXAMETHASONE

dexamethasone injection, solution

Product Information

Route of Administration

INTRAMUSCULAR, INTRAVENOUS

Active Ingredient/Active Moiety

ı	Ingredient Name	Basis of Strength	Strength
ı	DEXAMETHASONE (UNII: 7S517G31OL) (DEXAMETHASONE - UNII:7S517G31OL)	DEXAMETHASONE	2 mg in 1 mL

I	ackaging						
#	t Item Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:13985-533-03	100 mL in 1 VIAL, MULTI-DOSE					

2 NDC:13985-533-25	250 mL in 1 VIAL, MULTI-DOSE						
Marketing Information							
Manla dina Cata anno	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date				
Marketing Category	Application Number of Monograph Citation	Marketing Start Date	Marketing End Date				
ANADA	ANADA200324	07/27/2012	Marketing End Date				

Labeler - MWI (Vet One) (019926120)

Revised: 1/2018 MWI (Vet One)